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Abstract
Upon myocardial damage, the release of cardiac proteins induces a strong antibody-medi-
ated immune response, which can lead to adverse cardiac remodeling and eventually heart
failure (HF). Stem cell therapy using mesenchymal stromal cells (MSCs) or cardiomyocyte
progenitor cells (CPCs) previously showed beneficial effects on cardiac function despite low
engraftment in the heart. Paracrine mediators are likely of great importance, where, for
example, MSC-derived extracellular vesicles (EVs) also show immunosuppressive proper-
ties in vitro. However, the limited capacity of MSCs to differentiate into cardiac cells and the
sufficient scaling of MSC-derived EVs remain a challenge to clinical translation. Therefore,
we investigated the immunosuppressive actions of endogenous CPCs and CPC-derived
EVs on antibody production in vitro, using both healthy controls and end-stage HF patients.
Both MSCs and CPCs strongly inhibit lymphocyte proliferation and antibody production in
vitro. Furthermore, CPC-derived EVs significantly lowered the levels of IgG1, IgG4, and
IgM, especially when administered for longer duration. In line with previous findings, plasma
cells of end-stage HF patients showed high production of IgG3, which can be inhibited by
MSCs in vitro. MSCs and CPCs inhibit in vitro antibody production of both healthy and end-
stage HF-derived immune cells. CPC-derived paracrine factors, such as EVs, show similar
effects, but do not provide the complete immunosuppressive capacity of CPCs. The stron-
gest immunosuppressive effects were observed using MSCs, suggesting that MSCs might
be the best candidates for therapeutic targeting of B-cell responses in HF.
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Introduction
Cardiovascular disease (CVD) is the most common cause of death globally with almost 18 mil-
lion deaths per year [1]. A prominent CVD-subtype is ischemic heart disease (IHD), which is
characterized by myocardial cell death due to prolonged ischemia [2]. After subsequent reper-
fusion strategies, further myocardial damage is initiated by the release of cardiac proteins,
which can induce an inflammatory response [3,4]. Activated T- and B lymphocytes signifi-
cantly contribute to adverse cardiac remodeling via the production of pro-inflammatory cyto-
kines and antibodies [5–7], which can progress to severe heart failure (HF) [6,8–10].
Currently, progenitor cell therapy is gaining a lot of interest in order to regenerate the damaged
heart due to their regenerative properties and the ability to differentiate into other cell types [11–
13]. Mesenchymal stromal cells (MSCs) improve cardiac function by reducing scar size and
increasing left ventricular ejection fraction (LVEF) with 2–4% [14,15]. However, engraftment of
these cells in the heart is relatively poor, where less than 10% of the injected cells remain at the site
of injection [16,17]. In addition, the few remaining cells rarely differentiate into cardiac cells [18].
In addition to their regenerative capacity, MSCs have also been shown to suppress inflammatory
responses, antibody production, and fibrosis, mostly in a paracrine manner [19,20]. Important
paracrine mediators are extracellular vesicles (EVs), small lipid bi-layered vesicles containing lip-
ids, small RNAs and proteins, which are able to influence many processes including inflammation
[21,22]. Multiple studies investigated the therapeutic potency of MSCs and MSC derived EVs in
cardiovascular disease [13,23,24]. MSC-derived EVs were found to reduce infarct size and infiltra-
tion of immune cells into the affected myocardium after myocardial infarction (MI) in animal
models [25]. These findings suggest that the use of MSC-derived EVs might be a promising
strategy to restore cardiac function, however, technical difficulties in large scale production and
purification of MSC-EV are still limiting the translation to the clinic [19,26]. Considering the
developmental origin of endogenous cardiac-derived progenitor cells (CPCs), these cells might
prove better candidates for cell therapy for cardiac repair. Endogenous CPCs were previously
tested in several clinical trials where they improved cardiac function [12,27], especially when com-
bined with MSCs [28,29]. CPCs also have immunosuppressive properties, for example by inhibit-
ing T-cell proliferation, which is partly mediated by paracrine factors [30]. CPC-derived EVs are
proposed to be of great importance as paracrine mediators of these cells [31–33]. However, the
immunosuppressive capacity of CPCs or CPC-derived EVs on B cells and antibody-mediated
immune responses has not been elucidated yet. Therefore, we investigated the in vitro inhibitory
actions of CPCs and CPC-derived EVs on lymphocyte proliferation and the production of immu-
noglobulin subclasses, using immune cells from healthy controls and end-stage HF patients.
Material and methods
Culture of human-derived progenitor cells
Human bone marrow-derived mesenchymal stromal cells (MSCs) and cardiomyocyte progen-
itor cells (CPCs) were obtained and isolated as described before [34,35]. MSCs were cultured
in MEM-alpha (Gibco, 32561–037) supplemented with 10% fetal bovine serum (Gibco,
10270–106) + 1% PenStrep (Lonza, 17-602E) + 0.2 mM L-ascorbic acid-2-phospate (Sigma
A4034) + 1 ng/ml bFGF (Sigma F0291). CPCs were cultured in SP++ (25% EGM-2 (Lonza
CC-3156) + 75% M199 (Gibco 31150–022) supplemented with 10% fetal bovine serum + 1%
PenStrep + 1% non-essential amino acids (Lonza 13–114). Cultures were incubated at 37˚C
(5% CO2 and 20% O2) and adherent cells were passaged when reaching 80–90% of confluency
using trypsin digestion (0.25%, Lonza, CC-5012). MSCs and CPCs from fetal or adult donors
were used in the co-cultures between passage 6–17.
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Isolation of CPC-derived extracellular vesicles and Western blotting
CPC-derived EVs were isolated using size-exclusion chromatography (SEC), as previously
described [36]. In brief, fetal-derived CPCs were cultured until they reached a confluency of 80–
90%, after which the medium was replaced with serum-free medium (M-199, Gibco 31150–022).
After 24 h, conditioned medium (CM), containing the EVs, was collected, centrifuged at
2000g for 15 min, and filtered (0.45 μm) to remove dead cells and debris. Next, CM was con-
centrated using 100-kDA molecular weight cut-off Amicon spin filters (Merck Milipore) and
loaded onto a S400 highprep column (GE healthcare, Uppsala, Sweden) using an AKTA start
(GE Healthcare) containing an UV 280 nm flow cell. Fractions containing EVs were pooled
and filtered (0.45 μm) before further concentration procedures. The number of particles and
mean size distribution were measured using Nanoparticle Tracking Analysis (Nanosight
NS500, Malvern) as described before [36]. Protein concentration was measured using micro-
BCA protein assay kit (Thermo Scientific). Vesicle markers were assessed by Western blotting
(WB) as previously described [36]. EV protein fractions were loaded on pre-casted Bis-Tris
protein gels (ThermoFischer, NW04125BOX) and run for 1 h at 160V. Proteins were trans-
ferred to polyvinylidene difluoride (PVDF) membranes (Millipore, IPVH00010) and stained
for general EV markers [37] Alix (1:1000, Abcam, 177840), CD63 (1:1000, Abcam, 8219),
CD81 (1:1000, Santa Cruz, Sc-166029), or Calnexin (1:1000, Tebu-bio, GTX101676). Proteins
were detected using chemiluminescent peroxidase substrate (Sigma, CPS1120). Representative
pictures S1 Fig.
Isolation of peripheral mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh whole blood samples of
healthy controls or end-stage HF patients, in compliance with the declaration of Helsinki and
under approval of the Medical Ethics Committee Utrecht (METC, reference number 12/387).
Written informed consent for collection and biobanking of blood samples was obtained. End-
stage HF derived PBMCs were obtained from blood samples prior to heart transplantation.
PBMCs were isolated using Ficoll-plaque PLUS gradient (GE life sciences, 17-1440-03) accord-
ing to the manufacturers protocol. A total of 2,5x105 PBMCs were added per well (48-wells
plate) in RPMI-1640 medium (Lonza, BE12-702F) supplemented with 10% fetal bovine serum
and 1% PenStrep.
PBMC stimulation and co-culture with progenitor cells or purified EVs
For the stimulation of PBMCs and subsequent antibody production, a combination of IL-2 (120
IU/ml, BD Pharmingen, 554563) and PMA (0.123 ng/ml, Sigma, P8139) was used as previously
described [33]. PBMCs were co-cultured for 10 days, without medium change, in 48-well plates
(2.5x105 PBMC/well) with MSCs, CPCs (5.0x104 cells/well), or CPC-derived EVs (1x 10 μg =
6.3x1010 particles), immediately upon co-culture or 3x 10 μg (6.3x1010 particles) added every 3
days of co-culture. After 10 days of co-culture, light-microscopic images were taken using an
Olympus CKX41 microscope in combination with CellSense software. Non-adherent cells, con-
taining the lymphocytes, were collected and processed for further analysis using flow cytometry
(Gallios, Beckmann Coulter). Co-culture supernatant was collected, centrifuged at 500g for 10
min, aliquoted and stored at -80˚C for immunoglobulin measurements.
Lymphocyte proliferation
Flow cytometry (Gallios, Beckmann Coulter) was used to assess lymphocyte proliferation.
Prior to co-culture, PBMCs were labeled with 1.5mM carboxyfluorescein succinimidyl ester
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(CFSE, Sigma, 21888) as described previously [33]. In brief, PBMCs were incubated with CFSE
for 10 min at 37˚C in a dark shaking bath. After 10 minutes, 5% of FBS was used to prevent fur-
ther uptake. After two washing steps with PBS, PBMCs were incubated for 30 min with fluores-
cent antibodies, including CD3 for T cells (Brilliant Violet 510, Biolegend, 317332) and CD19
for B cells (PE/Cy5, Biolegend 302210). After washing with PBS, PBMCs were incubated for 30
min with a fixable viability dye (eFluor506, Bioscience, 65-0866-14) to exclude dead cells. Prior
to culture, general cell composition per donor was assessed by measuring the percentage of
CD3+ T cells and CD19+ B cells, to ensure that the cell populations were similar between the
different donors at baseline. Lymphocyte proliferation was calculated by measuring CFSE inten-
sity and the number of cells present in each division as described before [33]. Since we encoun-
tered some donor variations in the absolute number of proliferating cells in the stimulation
assays, the stimulated PBMC condition was considered as maximum response and defined as
100% proliferation (ratio = 1) and used for normalization of the data per donor and per experi-
ment. Data was analyzed using Kaluza Analysis Software (Beckman Coulter, version 1.3).
Immunoglobulin multiplex
The levels of IgM and IgG subclasses (IgG1, IgG2, IgG3, IgG4) in the co-cultures (5x diluted)
were measured using a Bio-Plex Pro™ human isotyping immunoassay 6-plex (Bio-Rad,
171A3100M) according to manufacturer’s instructions and were all within the detection limit
of the assay. Immunoglobulin levels in the supernatant after co-culture with MSC/CPC or
CPC-derived EVs were calculated using internal standards included in the assay. Immuno-
globulin levels are represented as relative production, with the stimulated PBMC condition
defined as 100% antibody production (ratio = 1) and used for normalization of the data per
donor and experiment.
Statistics
Statistical analysis and data representation were performed using IBM SPSS Statistics 21 and
Graphpad Prism (GraphPad Software Inc. version 8.01, San Diego CA, USA). Normal data
distribution was tested using the Kolmogorov-Smirnov test. Group comparison was per-
formed by a one-way ANOVA or Kruskal-Wallis test, corrected for multiple comparison test-
ing. Each individual PBMC donor is considered as an independent individual experimental
number (n), ranging from 2–8 donors per experiment. Data was considered significant with
two-tailed p-values <0.05 and is presented as mean ± SEM.
Results
Progenitor cells suppress lymphocyte proliferation upon cell-cell contact
To investigate the immunosuppressive effects of progenitor cells on the proliferation of lym-
phocytes, a co-culture using MSCs or CPCs was performed (Fig 1). To represent normal lym-
phocyte activation by antigen-presenting cells, the total PBMC population was used. After 10
days of co-culture, large clusters of proliferating T cells were visible upon stimulation with IL-
2 and PMA. These large clusters were smaller or even absent when PBMCs were cultured in
the presence of MSCs or CPCs (Fig 1A). Flow cytometry was used to measure CFSE intensity
and to assess lymphocyte proliferation (Fig 1B and 1C). FACS plots clearly showed active cell
proliferation upon stimulation with IL-2 and PMA and suppression of proliferation when
PBMCs were cultured with MSCs or CPCs. Quantification showed that both MSCs and CPCs
significantly decreased proliferation of lymphocytes by 64±18.6% and 19±12.5% respectively
(MSC p<0.0001, CPC p<0.05).
Mesenchymal- and cardiac progenitor cells for targeting of antibody-mediated immune responses in heart failure
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Production of IgM and different IgG subclasses is suppressed by cardiac-
derived progenitor cells
Next to reduced cell proliferation, MSCs are also able to inhibit several immune cell functions,
such as antibody secretion [38]. To examine whether this also holds true for CPCs, we col-
lected the supernatant after 10 days of co-culture and measured the levels of different immu-
noglobulin subclasses (Fig 2A). Since it is known that the age of the donor can affect their
inhibitory potency [39,40], both fetal and adult MSCs and CPCs were included. Adult and
fetal-derived MSCs significantly inhibited antibody production from stimulated PBMCs (Fig
2B–2F). Fetal and adult MSC significantly reduced the production of IgM (aMSC = 0.005±0.0
fMSC = 0.02±0.0; p<0.0001), IgG1 (aMSC = 0.24±0.06, fMSC = 0.28±0.06; p<0.0001), IgG3
Fig 1. Progenitor cells suppress lymphocyte proliferation. Lymphocyte proliferation was measured after 10 days of co-culture of PBMCs with MSCs or CPCs. A)
Representative microscopic images after 10 days of co-culture. Upon PBMC stimulation, large clusters of proliferating cells were observed. These large clusters were
absent in the presence of MSCs or CPCs. B) PBMCs were labeled with CFSE and lymphocyte proliferation was assessed by measuring CFSE intensity using flow
cytometry. FACS plots of non-stimulated lymphocytes show one peak of undivided cells, whereas upon stimulation, lymphocytes start to divide. C) Quantification of
lymphocyte proliferation, where stimulated lymphocytes were used as normalization. Both MSCs and CPCs show a significant decrease of lymphocyte proliferation
upon co-culture. Strongest effects were observed using MSCs, where proliferation was inhibited towards 36% compared to CPCs (81%). PBMC: pheripheral blood
mononuclear cells, MSC: mesenchymal stromal cell, CPC: cardiac progenitor cell. Per condition n = 4. Line bar indicates 200μm, magnification 4x. Significance was
determined using one-way ANOVA, � p<0.05, ���� p<0.0001.
https://doi.org/10.1371/journal.pone.0227283.g001
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Fig 2. Progenitor cells suppress the production of immunoglobulins. Antibody production was measured after 10 days of co-culture with fetal or adult-derived MSCs
or CPCs. A) Experimental design of the co-culture. B) Both fetal and adult MSCs showed strong immunosuppressive effects on the production of different
Mesenchymal- and cardiac progenitor cells for targeting of antibody-mediated immune responses in heart failure
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(aMSC = 0.19±0.06, fMSC = 0.25±0.09; p<0.0001) and IgG4 (aMSC = 0.29±0.07; p<0.01,
fMSC = 0.43±0.1; p<0.05). In addition, also CPCs showed strong suppressive effects on the
production of mainly IgM (aCPC = 0.02±0.0; p<0.0001, fCPC = 0.38±0.16; p<0.001), IgG1
(aCPC = 0.12±0.02; p<0.001, fCPC = 0.55±0.18; p<0.05) and IgG3 (aCPC = 0.06±0.0;
p<0.0001, fCPC = 0.44±0.14; p<0.001). For CPCs, the strongest immunosuppression was
observed using adult CPCs.
CPC-derived extracellular vesicles suppress antibody production, but are
not as effective as direct cell-cell interaction when using CPCs
To explore whether the suppressive capacity of CPC on antibody production is mediated by
paracrine factors, we assessed the potential of CPC-derived EVs (Fig 3). We experienced that it
is technically challenging to obtain sufficient MSC-derived EVs using SEC. Therefore, we only
included CPC-derived EVs in our co-cultures. Prior to co-culture, EVs were characterized
based on size distribution and the presence or absence of protein markers [37]. Isolated EVs
showed a representative size distribution profile with the highest peak at approximately 90 nm
(Fig 3A). In line with previous findings [36], WB analysis showed that CPC-derived EVs were
enriched for the typical EV proteins Alix, CD81, and CD63. Calnexin was only detectable in the
cell lysate, thereby confirming the absence of contaminations with other membrane compart-
ments (Fig 3B). An amount of 1x10 μg or 3x10 μg (every 3 days of co-culture) was added to the
PBMC cultures (Fig 3C). After 10 days of co-culture, antibody secretion was significantly sup-
pressed by EVs (Fig 3D). The production of IgM, IgG1, and IgG4 was significantly decreased
using the 3x dose of CPC-derived EVs (IgM = 0.35±0.05; p<0.05, IgG1 = 0.57±0.03; p<0.05,
and IgG4 = 0.66±0.0; p = 0.03), thereby indicating that long term suppression is more effective
than a single dose of EVs. However, the inhibitory effect was most robust when adding CPCs
and not CPC-derived EVs, with strongest suppressive effects on the release of IgG1 (0.59±0.1;
p<0.05), IgG2 (0.23±0.06; p = 0.02), IgG4 (0.53±0.03; p = 0.01) and IgM (0.17±0.03; p<0.01).
MSCs show the strongest immunosuppressive effects and are more likely to
be used as cell therapy in end-stage HF patients
Since we observed that CPC-derived EVs do not give the same degree of immunosuppression
as CPCs, we decided to continue with CPCs to examine their potential suppressive effect on
antibody-mediated immune responses in end-stage HF patients. PBMCs were isolated from
end-stage HF patients and cultured with or without MSCs/CPCs. (Fig 4). At baseline culture,
non-stimulated PBMCs derived from end-stage HF patients produced similar amounts of
IgGs with the exception of IgG3, which is, slightly but not significantly, increased compared to
PBMCs derived from healthy controls (Fig 4A). Upon co-culture of patient-derived PBMCs
with MSCs or CPCs, antibody production was significantly suppressed (Fig 4B and 4C).
Mainly MSCs showed strong suppressive effects, as they significantly decreased the production
of IgM (0.02±0.0; p<0.0001), as well as all IgG subclasses (IgG1 = 0.25±0.08; p = 0.001,
IgG2 = 0.03±0.02; p<0.0001, IgG3 = 0.25±0.08; p = 0.009, IgG4 = 0.19±0.07; p = 0.0006). Co-
cultures using CPCs showed similar suppressions, albeit at a lower level and the differences
were only statistically significant for IgM (0.20±0.06; p<0.0001) and IgG2 (0.31±0.14;
p = 0.0003).
immunoglobulin isotypes and subclasses. IgM, IgG1, IgG3, and IgG4 levels were significantly decreased upon co-culture with MSCs. For CPCs, strongest effects were
observed in cultures using adult-derived CPCs, where the production of IgM, IgG1, IgG3, and IgG4 was significantly suppressed. aMSC: adult-derived mesenchymal
stromal cell, fMSC: fetal-derived mesenchymal stromal cell, aCPC: adult-derived cardiac progenitor cell, fCPC: fetal-derived cardiac progenitor cell. For aMSC, fMSC and
fCPC n = 7, for aCPC n = 3. Significance was determined using One-way ANOVA, � p<0.05, �� p<0.01, ��� p<0.001, ���� p<0.0001.
https://doi.org/10.1371/journal.pone.0227283.g002
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Discussion
The post-MI immune response is an important contributor to adverse cardiac remodeling and
the development of HF [41–44]. The release of cardiac proteins upon MI can trigger antibody-
mediated immune responses, which further induce cardiac damage and heart failure [45–47].
Fig 3. Immunosuppressive capacity of CPC-derived EVs on immunoglobulin production. To assess whether CPC-derived paracrine factors can be used, EVs were
isolated and used in the PBMC co-cultures. A) EVs with a size of approximately 90 nm were isolated using SEC. B) WB of EVs and CL with general EV markers and
calnexin. C) Experimental setup of the co-culture model, where either CPCs or CPC-derived EVs with a total of 1x 10 μg or 3x 10 μg (every 3 days of co-culture) was
added to PBMCs. D) CPC-derived EVs showed a significant decrease of immunoglobulin production, especially when administered for a longer period of time. Levels of
IgM, IgG1, and IgG4 were significantly decreased when, every 3 days of co-culture, 10 μg of EVs were added to stimulated PBMCs. However, the strongest inhibition of
antibody production was observed when CPCs were used. CPC: cardiac progenitor cell, EV: extracellular vesicles, CL: cell lysate, SEC: size-exclusion chromatography,
PBMC: pheripheral blood mononuclear cells. For each condition n = 2, Significance was determined using One-way ANOVA, � p<0.05, �� p<0.01.
https://doi.org/10.1371/journal.pone.0227283.g003
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Stem cell therapy using progenitor cells, such as MSCs or CPCs, showed promising reparative
effects on cardiac function despite poor engraftment in the myocardium [17,48]. This indicates
that paracrine mediators, secreted by progenitor cells, can be of great importance. MSCs and
Fig 4. Inhibition of immunoglobulin production by progenitor cells in end-stage HF. The immunosuppressive actions of CPCs on antibody production in
end-stage HF was investigated using patient-derived PBMCs. A) Baseline antibody levels of unstimulated PBMCs in culture were measured and compared to
end-stage HF-derived PBMCs. Before co-culture with MSCs/CPCs, HF patients showed high levels of IgG1 and IgG3 compared to healthy controls. B)
Experimental set-up of the co-culture. C) Levels of IgM and IgG1-IgG4 were significantly decreased upon co-culture of patient-derived PBMCs with MSCs.
CPCs were able to significantly suppress IgM and IgG2, however, were not as potent as MSCs. MSC: mesenchymal stromal cell, CPC: cardiac progenitor cell, HF:
heart failure, PBMC: pheripheral blood mononuclear cells. Per condition n = 8. Significance was determined using a Kruskal Wallis test or One-way ANOVA, ��
p<0.01, ��� p<0.001, ���� p<0.0001.
https://doi.org/10.1371/journal.pone.0227283.g004
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MSC-derived EVs also have immunosuppressive properties, for example by lowering antibody
production in vitro [49,50]. However, the immunosuppressive capacity of endogenous CPCs
and CPC-derived EVs on B cells and antibody production has not been elucidated yet. Conse-
quently in this study, we investigated the immunosuppressive effects of CPCs and CPC-
derived paracrine mediators on antibody production using immune cells of both healthy con-
trols and end-stage HF patients.
In line with previous findings, we showed that both MSCs and CPCs significantly suppressed
proliferation of lymphocytes [30,32,38]. The suppressive effects of MSCs were more effective
than CPCs. The suppressive effects of MSCs and CPCs on effector and regulatory T cells have
been described before, where several studies show T cell inhibition via PDL-1/PD1 in a direct
cell communication manner [32,51]. Moreover, both MSCs and CPCs are also able to suppress
CD4+ T helper cell-mediated immune responses[52]. However, the interaction of progenitor
cells with B cells is still controversial and this issue has recently gained more interest[53–55].
MSCs can inhibit plasma cell formation and subsequent IgG production in a cell-cell contact
dependent as well as in an independent manner [38,55]. It is not known whether CPCs are also
able to suppress antibody production in vitro. We demonstrated that, similar to MSCs, CPCs
effectively suppress antibody production in vitro. We showed that both adult- and fetal-derived
CPCs significantly inhibit the levels of IgM, IgG1, and IgG3, of which IgM was most efficiently
suppressed, despite variation between different donors. These findings are in line with the
effects of MSC, where MSC are known to exert an inhibitory effect on T helper cells, B-cell dif-
ferentiation and class switching into IgG-producing cells [56,57]. Therefore, we could speculate
that CPC might use a similar mechanism, in which IgG production might be suppressed either
by inhibiting T-helper cell responses, thereby influencing B-cell activation and antibody pro-
duction, or by directly influencing B-cell differentiation and subsequent class-switching.
To facilitate clinical translation, we examined if the strong immunosuppressive effects of
CPCs and MSCs on antibody production using healthy donors, can be confirmed for IgG pro-
duction using HF patient-derived PBMCs. MSCs were able to significantly inhibit the produc-
tion of IgM and all IgG subclasses. For CPCs, the immunosuppressive effects were not as
potent compared to MSCs, where CPCs only significantly lowered the production of IgM and
IgG2. In end-stage HF, chronically activated immune cells progressively worsen cardiac func-
tion, for example by the production of cardiac antibodies [58,59]. Our findings indicate that
progenitor cells, preferably MSCs, might be used as therapeutic agents to suppress antibody-
mediated immune responses as observed in end-stage HF. However, mimicking the physiolog-
ical immune response in vitro, as observed in end-stage HF patients, is still complicated.
Therefore, these findings still have to be validated in vivo.
Part of the immunosuppressive properties of MSCs is mediated by paracrine factors, such
as EVs [19,21]. The advantage of using EVs is that they can be used as a cell-free approach,
thereby increasing safety, and allowing a longer duration of the treatment [19,26]. However,
high variability in quantity and quality in the scaling and production process of MSC-derived
EVs has been a limitation [26]. CPC-derived EVs might provide a promising alternative, not
only due to their regenerative and immune modulating capacities [60], but also for their cul-
ture scalability. CPC-derived EVs have immunosuppressive effects on T cells [30,60], however,
the effects on B cells and antibody-mediated responses is not clear. Our findings showed that
CPC-derived EVs lower the different immunoglobulin isotypes and subclasses, such as IgM,
IgG1, and IgG4. However, the number of EVs needed to reach similar suppressive effects com-
pared to CPCs, remains challenging. In this study, we were only able to test EVs produced by
fetal CPCs due to technical difficulties in obtaining sufficient numbers of EVs from adult
CPCs. Fetal-derived progenitor cells might exert different effects than adult-derived cells,
where, for example, adult-derived MSCs show stronger immunosuppressive capacities relative
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to fetal-derived MSCs [61]. For CPCs, it has been described that fetal- and adult-derived CPCs
have different developmental potentials, and adult CPCs may be more effective in cardiac
repair [62,63]. In addition, fetal-derived CPCs are highly proliferative as compared to adult-
derived cells. Due to this proliferative state CPCs may secrete a different palette of paracrine
factors that are more associated to cell cycle rather than immunomodulation. Therefore, the
effects of EVs from adult CPCs may differ from fetal–derived CPCs and have to be investigated
in future studies. Nonetheless, from our data, it is clear that EVs can be used as immunosup-
pressive mediators, but do completely cover the strong immunosuppressive effect of CPCs.
In conclusion, we demonstrated immunosuppressive actions of both MSCs and CPCs on
lymphocyte proliferation and antibody production, with strongest effects observed when using
MSCs. These are partly mediated by EVs, in a time-dependent matter. Lastly, we showed that
CPCs and especially MSCs were able to suppress antibody production by patient-derived cells,
thereby indicating the therapeutic potential of progenitor cells in HF. Currently, cell therapy
using MSCs is no longer the holy grail for true cardiac regeneration and cell replacement ther-
apy, however, MSCs might be promising candidates for targeting the post-MI immune
response and HF progression. Future studies should focus on the identification of the cardiac
antigens which are targeted by the produced IgGs and on the potential of combination thera-
pies, using both MSCs and CPCs, to simultaneously target cardiac regeneration and antibody-
mediated immune responses.
Supporting information
S1 Fig. Extracellular vesicle markers. Proper isolation of extracellular vesicles (EV) was deter-
mined by the presence of CD63, CD81 and Alix and absence of the cellular marker Calnexin
by Western Blotting. Cell lysates (Cl) were used as controls.
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